Cited by 5,198PARP inhibition in cancer therapyDNA Repair MechanismsBRCA gene mutations in cancer

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Open access

Bryant, Helen E., Schultz, Niklas, Thomas, Huw D., Parker, Kayan M., Flower, Dan, Lopez, Elena, Kyle, Suzanne, Meuth, Mark, Curtin, Nicola J., Helleday, Thomas·2005·Nature

DOI 10.1038/nature03443

Open this paper in CoChat — free account

Abstract

Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage. Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumours. Here, we show that PARP inhibitors trigger gamma-H2AX and RAD51 foci formation. We propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair. Furthermore, we show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired. Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells. We exploit this requirement in order to kill BRCA2-deficient tumours by PARP inhibition alone. Treatment with PARP inhibitors is likely to be highly tumour specific, because only the tumours (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination. The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumour, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.

Integrity signals

Registry

Crossref · 10.1038/nature03443

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage
Paull, T. T., Rogakou, E. P., Yamazaki, V., Kirchgessner, C. U., Gellert, M., & Bonner, W. M. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00610-2 · Cited by 2,098
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
D’Amours, D., Desnoyers, S., D’Silva, I., & Poirier, G. G. (1999) · Biochemical Journal · doi:10.1042/bj3420249 · Cited by 1,819
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713
Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M. P., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7303 · Cited by 1,058
A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage
El‐Khamisy, S. F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg761 · Cited by 689
Functional interaction between PARP‐1 and PARP‐2 in chromosome stability and embryonic development in mouse
Murcia, J. M., Ricoul, M., Tartier, L., Niedergang, C., Huber, A., Dantzer, F., Schreiber, V., Amé, J., Dierich, A., LeMeur, M., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg206 · Cited by 629
Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks
Lindahl, T. L., Satoh, M. S., Poirier, G. G., & Klungland, A. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89089-1 · Cited by 611
PARP is important for genomic stability but dispensable in apoptosisPreprint
Wang, Z., Stingl, L., Morrison, C. G., Jantsch, M. F., Łoś, M., Schulze‐Osthoff, K., & Wagner, E. F. (1997) · Genes & Development · doi:10.1101/gad.11.18.2347 · Cited by 557

Flagged first, then by citations

Show all 26 references

Sorted by citations

Items 701–800 of 1,021

Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance
Michelena, J., Lezaja, A., Teloni, F., Schmid, T., Imhof, R., & Altmeyer, M. (2018) · Nature Communications · doi:10.1038/s41467-018-05031-9 · Cited by 117
A Focused DNA-Encoded Chemical Library for the Discovery of Inhibitors of NAD + -Dependent Enzymes
Yuen, L. H., Dana, S., Liu, Y., Bloom, S. I., Thorsell, A. G., Neri, D., Donato, A. J., Kireev, D., Schuler, H., & Franzini, R. M. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b08039 · Cited by 117
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
Lesueur, P., Lequesne, J., Grellard, J., Dugué, A. E., Coquan, E., Brachet, P.-E., Geffrelot, J., Kao, W., Emery, É., Berro, D. H., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5413-y · Cited by 117
BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
Boussios, S., Rassy, E., Moschetta, M., Ghose, A., Adeleke, S. M., Sanchez, E., Sheriff, M., Chargari, C., & Pavlidis, N. A. (2022) · Cancers · doi:10.3390/cancers14163888 · Cited by 117
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations
Bayraktar, S., Gutierrez‐Barrera, A. M., Liu, D., Tasbas, T., Akar, U., Litton, J. K., Lin, E., Albarracin, C. T., Meric‐Bernstam, F., Gonzalez-Angulo, A. M., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1711-z · Cited by 117
PTIP associates with Artemis to dictate DNA repair pathway choicePreprint
Wang, J., Asaithamby, A., Löbrich, M., Li, Y., Chen, D. J., Chen, J., & Gong, Z. (2014) · Genes & Development · doi:10.1101/gad.252478.114 · Cited by 117
FIGL1 and its novel partner FLIP form a conserved complex that regulates homologous recombination
Fernandes, J. B., Duhamel, M., Seguéla-Arnaud, M., Froger, N., Girard, C., Choinard, S., Solier, V., De Winne, N., De Jaeger, G., Gevaert, K., et al. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007317 · Cited by 116
“Targeting HR protein could increase the sensitivity of cancer cells to anti-cancer drugs [52].”
Background
The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
Lorenzo, S. B. D., Patel, A. G., Hurley, R. M., & Kaufmann, S. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00228 · Cited by 116
Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
Philip, C., Laskov, I., Beauchamp, M.-C., Marques, M., Amin, O., Bitharas, J., Kessous, R., Kogan, L., Baloch, T., Gotlieb, W. H., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3639-0 · Cited by 116
PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
Wang, L., Liang, C., Li, F., Guan, D., Wu, X., Fu, X., Lü, A., & Zhang, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102111 · Cited by 116
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
Jiang, X., Li, W., Li, X., Bai, H., & Zhang, Z. (2019) · Cancer Management and Research · doi:10.2147/cmar.s200524 · Cited by 116
Poly(ADP-ribose) polymerase enzymes and the maintenance of genome integrity
Eisemann, T., & Pascal, J. M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03366-0 · Cited by 116
Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors
Luo, Y., Xia, Y., Liu, D., Li, X., Li, H., Liu, J., Zhou, D., Dong, Y. J., Li, X., Qian, Y., et al. (2024) · Cell · doi:10.1016/j.cell.2024.06.013 · Cited by 120
DNA Repair by Homologous Recombination, But Not by Nonhomologous End Joining, Is Elevated in Breast Cancer Cells
Mao, Z., Jiang, Y., Liu, X., Seluanov, A., & Gorbunova, V. A. (2009) · Neoplasia · doi:10.1593/neo.09312 · Cited by 116
Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90
Dungey, F. A., Caldecott, K. W., & Chalmers, A. J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0201 · Cited by 116
A phosphorylation–deubiquitination cascade regulates the BRCA2–RAD51 axis in homologous recombinationPreprint
Luo, K., Li, L., Li, Y., Wu, C., Yin, Y., Chen, Y., Deng, M., Nowsheen, S., Yuan, J., & Lou, Z. (2016) · Genes & Development · doi:10.1101/gad.289439.116 · Cited by 116
Nuclear PARPs and genome integrityPreprint
Azarm, K., & Smith, S. H. (2020) · Genes & Development · doi:10.1101/gad.334730.119 · Cited by 116
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Arena, S., Corti, G., Durinikova, E., Montone, M., Reilly, N. M., Russo, M., Lorenzato, A., Arcella, P., Lazzari, L., Rospo, G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2409 · Cited by 115
The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
Arun, B., Akar, U., Gutierrez‐Barrera, A. M., Hortobágyi, G. N., & Özpolat, B. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3003 · Cited by 115
Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer
Konstantinopoulos, P. A., Wilson, A. J., Saskowski, J. L., Wass, E., & Khabele, D. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.03.007 · Cited by 115
Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells
Verhagen, C. V. M., de Haan, R., Hageman, F., Oostendorp, T. P. D., Carli, A. L. E., O’Connor, M. J., Jonkers, J., Verheij, M., van den Brekel, M. W. M., & Vens, C. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.03.028 · Cited by 115
Targeting homologous recombination repair defects in cancer
Evers, B., Helleday, T., & Jonkers, J. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.06.001 · Cited by 115
Self-citation
The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations
Fatouros, M., Baltoyiannis, G., & Roukos, D. H. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9612-4 · Cited by 115
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
Vollebergh, M. A., Lips, E. H., Nederlof, P. M., Wessels, L. F. A., Wesseling, J., van de Vijver, M. J., de Vries, E. G. E., van Tinteren, H., Jonkers, J., Hauptmann, M., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3655 · Cited by 114
Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness
Kari, V., Mansour, W. Y., Raul, S. K., Baumgart, S. J., Mund, A., Grade, M., Sirma, H., Simon, R., Will, H., Dobbelstein, M., et al. (2016) · EMBO Reports · doi:10.15252/embr.201642352 · Cited by 115
PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers
Murai, J., & Pommier, Y. G. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055914 · Cited by 114
Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function
Gui, B., Gui, F., Takai, T., Feng, C., Bai, X., Fazli, L., Dong, X., Liu, S., Zhang, X., Zhang, W., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908547116 · Cited by 114
BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects
Wong, W., Raufi, A. G., Safyan, R. A., Bates, S. E., & Manji, G. A. (2020) · Cancer Management and Research · doi:10.2147/cmar.s211151 · Cited by 114
CARM1 regulates replication fork speed and stress response by stimulating PARP1
Genois, M., Gagné, J., Yasuhara, T., Jackson, J., Saxena, S., Langelier, M.-F., Ahel, I., Bedford, M. T., Pascal, J. M., Vindigni, A., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2020.12.010 · Cited by 114
DNA Repair Proteins as Molecular Targets for Cancer Therapeutics
Kelley, M. R., & Fishel, M. L. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008784220294 · Cited by 114
Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53 -Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin
Hay, T., Matthews, J. R., Pietzka, L., Lau, A., Cranston, A. N., Nygren, A. O. H., Douglas-Jones, A. G., Smith, G. C. M., Martin, N. M. B., O’Connor, M. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2388 · Cited by 114
Ferulic acid decreases cell viability and colony formation while inhibiting migration of MIA PaCa-2 human pancreatic cancer cells in vitro
Fahrioğlu, U., Dodurga, Y., Elmas, L., & Seçme, M. (2015) · Gene · doi:10.1016/j.gene.2015.10.061 · Cited by 113
Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis
McGurk, L., Mojsilovic‐Petrovic, J., Deerlin, V. M. V., Shorter, J., Kalb, R. G., Lee, V. M., Trojanowski, J. Q., Lee, E. B., & Bonini, N. M. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0586-1 · Cited by 115
Multiple roles of DNA2 nuclease/helicase in DNA metabolism, genome stability and human diseases
Zheng, L., Meng, Y., Campbell, J. L., & Shen, B. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1101 · Cited by 113
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
Chiappa, M., Guffanti, F., Bertoni, F., Colombo, I., & Damia, G. L. M. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100744 · Cited by 113
The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer
Tommiska, J., Bártková, J., Heinonen, M., Hautala, L. C., Kilpivaara, O., Eerola, H., Aittomäki, K., Hofstetter, B., Lukáš, J., von Smitten, K., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210885 · Cited by 113
An update on PARP inhibitors for the treatment of cancer
Hall, M., & Benafif, S. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s30793 · Cited by 112
PARP1 Inhibitors: Antitumor Drug Design
Maluchenko, N. V., Kotova, E. Y., Kulaeva, O. I., Kirpichnikov, M. P., & Studitskiy, V. M. (2015) · Acta Naturae · doi:10.32607/20758251-2015-7-3-27-37 · Cited by 112
DNA damage-induced nuclear factor-kappa B activation and its roles in cancer progression
Wang, W., Mani, A. M., & Wu, Z. (2017) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.03 · Cited by 112
Synthetically Lethal Interactions of ATM, ATR, and DNA-PKcs
Kantidze, O. L., Velichko, A. K., Luzhin, A. V., Petrova, N. V., & Razin, S. V. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.09.007 · Cited by 112
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
Jette, N., Kumar, M., Radhamani, S., Arthur, G., Goutam, S., Yip, S., Kolinsky, M. P., Williams, G. J., Bose, P., & Lees‐Miller, S. P. (2020) · Cancers · doi:10.3390/cancers12030687 · Cited by 112
Discovery of synthetic lethal and tumor suppressor paralog pairs in the human genome
Parrish, P. C. R., Thomas, J. D., Gabel, A. M., Kamlapurkar, S., Bradley, R. K., & Berger, A. H. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109597 · Cited by 112
Clinical approaches to overcome PARP inhibitor resistance
Zou, Y., Zhang, H., Chen, P., Tang, J., Yang, S., Nicot, C., Guan, Z., Li, X., & Tang, H. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02355-1 · Cited by 118
Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers
Powell, C. B., Mikropoulos, C., Kaye, S. B., Nutting, C. M., Bhide, S., Newbold, K. L., & Harrington, K. J. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.03.003 · Cited by 112
Drug Resistance Caused by Reversion Mutation
Ashworth, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2287 · Cited by 112
DNA damage response and prostate cancer: defects, regulation and therapeutic implications
Karanika, S., Karantanos, T., Li, L., Corn, P. G., & Thompson, T. C. (2014) · Oncogene · doi:10.1038/onc.2014.238 · Cited by 111
Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity
Choudhury, A., Zhao, H. W., Jalali, F., Rashid, S. A., Ran, J., Supiot, S., Kiltie, A. E., & Bristow, R. G. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0959 · Cited by 111
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Perez‐Gracia, J. L., Sanmamed, M. F., Bosch, A., Patiño‐García, A., Schalper, K. A., Segura, V., Joaquim Bellmunt, B., Tabernero, J. M., Sweeney, C. J., Choueiri, T. K., et al. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.005 · Cited by 112
Endogenous DNA 3′ Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 Nuclease
Álvarez-Quilón, A., Wojtaszek, J. L., Mathieu, M., Patel, T., Appel, C. D., Hustedt, N., Rossi, S. E., Wallace, B. D., Setiaputra, D., Adam, S., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.021 · Cited by 111
Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes
Patel, A. G., Flatten, K. S., Schneider, P. A., Dai, N. T., McDonald, J. S., Poirier, G. G., & Kaufmann, S. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.296475 · Cited by 111
Epigenetic Modifications in Breast Cancer and Their Role in Personalized Medicine
Stefánsson, Ó. A., & Esteller, M. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.04.033 · Cited by 111
Molecular Pathways: Targeting PARP in Cancer Treatment
Do, K. T., & Chen, A. P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0163 · Cited by 111
Exploiting synthetic lethal interactions for targeted cancer therapy
Reinhardt, H. C., Jiang, H., Hemann, M. T., & Yaffe, M. B. (2009) · Cell Cycle · doi:10.4161/cc.8.19.9626 · Cited by 110
Synthesis and Evaluation of a New Generation of Orally Efficacious Benzimidazole-Based Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors as Anticancer Agents
Tong, Y., Bouska, J. J., Ellis, P. A., Johnson, E. F., Leverson, J. D., Liu, X., Marcotte, P. A., Olson, A. M., Osterling, D. J., Przytulinska, M., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900697r · Cited by 110
Molecular Pathways: Understanding the Role of Rad52 in Homologous Recombination for Therapeutic Advancement
Lok, B. H., & Powell, S. N. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3150 · Cited by 110
The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality
Papadimitriou, M., Mountzios, G., & PAPADIMITRIOU, C. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.010 · Cited by 110
RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance
Wang, Y., Krais, J. J., Bernhardy, A. J., Nicolas, É., Cai, K. Q., Harrell, M. I., Kim, H. H., George, E. M., Swisher, E. M., Simpkins, F. A., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87033 · Cited by 110
Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers
Okazaki, A., Gameiro, P. A., Christodoulou, D. C., Laviolette, L. A., Schneider, M., Chaves, F. L., Stemmer-Rachamimov, A. O., Yazinski, S. A., Lee, R. E., Jr., Stephanopoulos, G. N., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87800 · Cited by 110
Targeting Cancer with a Lupus Autoantibody
Hansen, J. E., Chan, G., Liu, Y., Hegan, D. C., Dalal, S., Dray, E. V., Kwon, Y., Xu, Y., Xu, X., Peterson-Roth, E., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004385 · Cited by 109
Genetic predisposition to pancreatic cancer
Ghiorzo, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i31.10778 · Cited by 109
FIGNL1-containing protein complex is required for efficient homologous recombination repair
Yuan, J., & Chen, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220662110 · Cited by 109
Role of Mitochondria in Cancer Stem Cell Resistance
García-Heredia, J. M., & Carnero, A. (2020) · Cells · doi:10.3390/cells9071693 · Cited by 109
Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs
Wu, Q., Siddharth, S., & Sharma, D. (2021) · Cancers · doi:10.3390/cancers13153697 · Cited by 110
Going Ape as an Approach to Cancer Therapeutics
Bapat, A., Fishel, M. L., & Kelley, M. R. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2008.2218 · Cited by 109
The role of BRCA1 in DNA double-strand repair: Past and present
Caestecker, K. W., & Van de Walle, G. R. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.11.013 · Cited by 108
Integrating the DNA damage and protein stress responses during cancer development and treatment
Gorgoulis, V. G., Pefani, D., Pateras, I. S., & Trougakos, I. P. (2018) · The Journal of Pathology · doi:10.1002/path.5097 · Cited by 108
A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments
Mohni, K. N., Thompson, P. S., Luzwick, J. W., Glick, G. G., Pendleton, C. S., Lehmann, B. D., Pietenpol, J. A., & Cortez, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125482 · Cited by 108
DNA repair genes are selectively mutated in diffuse large B cell lymphomas
de Miranda, N. F. C. C., Peng, R., Georgiou, K. E., Wu, C., Falk-Sörqvist, E., Berglund, M., Chen, L., Gao, Z., Lagerstedt‐Robinson, K., Lisboa, S., et al. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20122842 · Cited by 108
How cancer cells hijack DNA double-strand break repair pathways to gain genomic instability
Jeggo, P. A., & Löbrich, M. (2015) · Biochemical Journal · doi:10.1042/bj20150582 · Cited by 108
ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma
Schmitt, A., Knittel, G., Welcker, D., Yang, T.-P., George, J., Nowak, M., Leeser, U., Büttner, R., Perner, S., Peifer, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3398 · Cited by 109
Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition
Hou, D., Xu, G., Zhang, C., Li, B., Qin, J., Hao, X., Liu, Q., Zhang, X., Liu, J., Wei, J., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.471 · Cited by 108
Pharmacologic characterization of fluzoparib, a novel poly( ADP ‐ribose) polymerase inhibitor undergoing clinical trials
Wang, L., Yang, C., Xie, C., Jiang, J., Gao, M., Li, F., Li, Y., Bao, X., Fu, H., & Lou, L. (2019) · Cancer Science · doi:10.1111/cas.13947 · Cited by 108
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome
Cecere, S. C., Giannone, G., Salutari, V., Arenare, L., Lorusso, D., Ronzino, G., Lauria, R., Cormio, G., Carella, C., Scollo, P., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.10.023 · Cited by 108
The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment
Juhász, S., Smith, R., Schauer, T., Spekhardt, D., Mamar, H., Zentout, S., Chapuis, C., Huet, S., & Timinszky, G. (2020) · Science Advances · doi:10.1126/sciadv.abb8626 · Cited by 108
Poly(ADP-ribosyl)ation in mammalian ageing
Beneke, S., & Bürkle, A. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm735 · Cited by 108
c-MYC Suppresses BIN1 to Release Poly(ADP-Ribose) Polymerase 1: A Mechanism by Which Cancer Cells Acquire Cisplatin Resistance
Pyndiah, S., Tanida, S., Ahmed, K. M., Cassimere, E. K., Choe, C., & Sakamuro, D. (2011) · Science Signaling · doi:10.1126/scisignal.2001556 · Cited by 108
Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells
Schoonen, P. M., Talens, F., Stok, C., Gogola, E., Heijink, A. M., Bouwman, P., Foijer, F., Tarsounas, M., Blatter, S., Jonkers, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15981 · Cited by 108
Targeting DNA damage and repair: Embracing the pharmacological era for successful cancer therapy
Aziz, K., Nowsheen, S., Pantelias, G. E., Iliakis, G. E., Gorgoulis, V. G., & Georgakilas, A. G. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.010 · Cited by 107
Making the best of PARP inhibitors in ovarian cancer
Banerjee, S. N., Kaye, S. B., & Ashworth, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.116 · Cited by 107
Searching for synthetic lethality in cancer
Brough, R., Frankum, J. R., Costa-Cabral, S., Lord, C. J., & Ashworth, A. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.009 · Cited by 107
Resistance to PARP-Inhibitors in Cancer Therapy
Montoni, A., Robu, M., Pouliot, É., & Shah, G. M. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00018 · Cited by 107
The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer
Weberpals, J. I., Garbuio, K., O'Brien, A., Clark-Knowles, K. V., Doucette, S. P., Antoniouk, O., Goss, G. D., & Dimitroulakos, J. (2008) · International Journal of Cancer · doi:10.1002/ijc.23987 · Cited by 107
Holliday junction processing enzymes as guardians of genome stability
Sarbajna, S., & West, S. C. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.07.003 · Cited by 107
Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells
Goldberg, M. S., Xing, D., Ren, Y., Oršulić, S., Bhatia, S. N., & Sharp, P. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016538108 · Cited by 107
Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics
Yap, T. A., & Workman, P. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134532 · Cited by 107
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
Evans, T., & Matulonis, U. A. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016687254 · Cited by 107
Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
Gralewska, P., Gajek, A., Marczak, A., & Rogalska, A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00874-6 · Cited by 107
The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences
Pan, J. W., Zabidi, M. M. A., Ng, P.-S., Meng, M., Hasan, S. N., Sandey, B., Sammut, S., Yip, C. H., Rajadurai, P., Rueda, O. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20173-5 · Cited by 107
Exploiting replication gaps for cancer therapy
Cong, K., & Cantor, S. B. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.04.023 · Cited by 107
Hereditary Breast Cancer and the BRCA1-Associated FANCJ/BACH1/BRIP1
Cantor, S. B., & Guillemette, S. (2011) · Future Oncology · doi:10.2217/fon.10.191 · Cited by 106
“nn Along with [5], this landmark paper”
Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
O'Sullivan, C. C., Moon, D. H., Kohn, E. C., & Lee, J. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00042 · Cited by 106
DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer
Velic, D., Couturier, A. M., Ferreira, M., Rodrigue, A., Poirier, G. G., Fleury, F., & Masson, J. (2015) · Biomolecules · doi:10.3390/biom5043204 · Cited by 106
Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach
Boussios, S., Karihtala, P., Moschetta, M., Abson, C., Karathanasi, A., Zakynthinakis-Kyriakou, N., Ryan, J. E., Sheriff, M., Rassy, E., & Pavlidis, N. A. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00867-4 · Cited by 106
Targeted Brain Tumor Radiotherapy Using an Auger Emitter
Pirovano, G., Jannetti, S. A., Carter, L. M., Sadique, A., Kossatz, S., Guru, N., França, P. D. D. S., Maeda, M., Zeglis, B. M., Lewis, J. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2440 · Cited by 106
PARP Inhibitors for Breast Cancer Treatment
Morganti, S., Marra, A., Angelis, C. D., Toss, A., Licata, L., Giugliano, F., Salimbeni, B. T., Giachetti, P. P. M. B., Espósito, A., Giordano, A., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.7322 · Cited by 106
Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
Cidado, J. R., & Park, B. H. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9264-2 · Cited by 106
Inhibition of poly(ADP-ribose) polymerase in cancer
Plummer, E. R. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.02.004 · Cited by 106
Rad51 and BRCA2 - New Molecular Targets for Sensitizing Glioma Cells to Alkylating Anticancer Drugs
Quirós, S., Roos, W. P., & Kaina, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027183 · Cited by 106
6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
Issaeva, N., Thomas, H. D., Djurenovic, T., Jaspers, J. E., Stoimenov, I., Kyle, S., Pedley, N., Gottipati, P., Zur, R., Sleeth, K. M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3416 · Cited by 106
Self-citation
Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome
Roukos, D. H., & Briasoulis, E. C. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0930 · Cited by 106

Authors: Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T.
Affiliations: University of Sheffield (GB)
Stockholm University (SE)
Newcastle University (GB)
Corresponding author: Helleday, Thomas
ORCID: Bryant, Helen E.
Thomas, Huw D.
Curtin, Nicola J.
Helleday, Thomas
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2005-04-14
Volume: 434
Issue: 7035
Pages: 913-917
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature03443
OpenAlex: W2009007206
Cited by: 5,198
References: 26
Citations by year: 2026: 213 · 2025: 256 · 2024: 286 · 2023: 355 · 2022: 355 · 2021: 396 · 2020: 388 · 2019: 282 · 2018: 290 · 2017: 273 · 2016: 265 · 2015: 230 · 2014: 243 · 2013: 223 · 2012: 213
FWCI: 56.59
Type: journal article
Language: en
Update notices: erratum (2007-05-17)
Open access: green
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Newcastle University ePrints (Newcastle Univesity)
Funders: National Cancer Institute (F31CA260794)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: PARP inhibitors, BRCA2 deficiency, homologous recombination, synthetic lethality, breast cancer, PARP1, DNA repair, replication fork collapse, single-strand breaks, γH2AX foci, RAD51 foci, base excision repair
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Benzodiazepines, DNA Damage, DNA Repair, DNA Replication, Mice, Nude, Neoplasms, Poly(ADP-ribose) Polymerases, Xenograft Model Antitumor Assays, Genes, BRCA2, BRCA2 Protein, Cell Line, Tumor, Mice, Azulenes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks